To provide further assistance, ongoing clinical trials are assessing the combination of CAR-M (CT-0508) and KEYTRUDA® (pembrolizumab), an anti-PD1 therapy, in the treatment of HER2-overexpressing cancer in humans. The gene discussed is ERBB2; the disease is cancer.